Rilvegostomig is the experimental treatment being tested in this study. It is given through an intravenous infusion and is intended to work alongside chemotherapy to treat advanced biliary tract cancer.

Durvalumab is a medication used as a comparison in this trial. It is an immunotherapy delivered through an intravenous infusion that helps the body’s immune system recognize and attack cancer cells, and it is administered in combination with chemotherapy.

Gemcitabine is a type of chemotherapy medication given through an intravenous infusion to help kill cancer cells.

Cisplatin is a chemotherapy medication administered through an intravenous infusion used to treat cancer by interfering with the growth of cancer cells.

Infliximab is a medication used as background therapy, which is typically used to manage inflammation or immune responses, and is given through an intravenous infusion.

Mycophenolate mofetil is a medication used as background therapy that works by suppressing the immune system, and it is taken orally.

Biliary Tract Cancer – This is a type of cancer that starts in the bile ducts, which are the tubes that carry bile from the liver to the gallbladder and small intestine. It can develop in the ducts inside the liver or in the ducts outside the liver. The disease typically progresses as abnormal cells grow uncontrollably within these channels. As the cancer grows, it can block the flow of bile through the body. This progression can lead to changes in how the liver functions and how the digestive system processes nutrients.